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Abstract-A

mathematicalmodel is used to discussthe effects of cycle-specificchemotherapy.

The model includes a constraint equation which describes the effects of the drugs on sensitive normal tissue such as bone marrow.
This model investigates both pulsed and piecewisscontinuous
chemotherapeutic effects and calculates the parameter regions of acceptable dose and period. It also
identifies the optimal period needed for maximal tumor reduction. Examples are included concerning
the use of growth factors and how they can enhance the cell kill of the chemotherapeutic drugs.

Keywords-Periodic

differentialequation,Cancer,Chemotherapy,Cell-cycle,Quiescence.
1. INTRODUCTION

Many chemotherapeutic drugs are cycle-specific: they only destroy cells in specific phases of their
cycle. Some examples of these types of drugs are Cytosine Arabinoside (AraX!), 5fluorouracil
and Prednisone which work in the G1 and S phase of the cell-cycle and Vincristine and Bleomycin
which work in the M phase of the cell-cycle. Most of the clinically-used methods of delivering
chemotherapy have been developed empirically, and as stated by Birkhead et al. [l], “In the absence of more effective new drugs there is an increasing need to define better treatment strategies
with existing agents.” The object of the model in this paper is to give some qualitative ideas on
how to better administer cycle-specific chemotherapy. This model is not meant to dictate to the
clinician which regimens of therapy are appropriate, for each individual patient is different and
requires quantitatively different treatments. In fact, in most cases even approximate ranges for
parameters and drug effects are not known (R. Perry, private communication). But, it is hoped
that this model will give some qualitative ideas on how to better implement cycle-specific therapy.
Some of the more recent work done with mathematical models of cycle-specific chemotherapy
is by Webb [2,3]. He develops both linear and nonlinear models of cycle-specific chemotherapy.
In the case of the linear model, the advantages of periods of dose with shorter duration are
investigated. Another work of interest is by Birkhead et al. [l] in which a four-compartment
linear system is developed to model the cycling, resistant, and resting cells. Their results are
limited to a few numerical calculations on four specific types of treatments. Swan [4] also examines
cycle-specific chemotherapy in his review article. In particular, he concentrates on age-structured
I would like to thank R. Perry for his extremely useful comments and discussions which helped me immensely in
preparing this paper. Also, I would like to thank S. Michelson for his helpful insight into much of the mechanisms
of cancer. This paper is a partial requirement for the completion of a Ph.D. in the Department of Mathematics
and Statistics at Old Dominion University.
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models which take into account the age of the cells in each compartment
of the cell cycle. He
also studies an age-structured
chemotherapeutic
model of acute myeloid leukemia (AML). Eisen
and Schiller [S] study a two-compartment
model of tumor growth with nonconstant
growth rate.
In addition, Kuzma et al. [6] examine a model with exponential
growth for the tumor and both
immediate and delayed effects of drugs. In their model, they study a variety of results including
the number
tumor

of doses needed

reduction,

for a specific tumor

and some toxicity

reduction,

the minimum

effects. The issue not discussed

initial

dose needed

in any of these articles

for

is the

effects of the drugs on normal tissue. An interesting
approach to the problem of toxicity to bone
marrow and other sensitive tissues has been investigated
by Agur et al. [7] and Cojocaru and
Agur [8] (this adds age structure to the previous). They develop criteria to maximize the tumor
cell kill while minimizing
bone marrow damage. They accomplish this by examining the relation
between

the period

in which the drugs are delivered

and the cell-cycle

time for the tumor

and

bone marrow cells. The idea is to administer
the chemotherapeutic
drug when the cancer cells
are in a more vulnerable phase (S) and the bone marrow is in a less vulnerable stage. These two
articles
growth

also differ from the other above articles in the fact that they only consider
phase of the cell cycle, i.e., they do not consider the resting stage (Go).

cells in the

The model in this paper will extend the linear models described in [1,2,5] by adding both
pulsed and piecewise-continuous
chemotherapy
along with the constraint to the chemotherapeutic
regimen obtained by examining the effects of the cycle-specific drug on the normal tissue. The
tissues that will concern us in particular are the fast proliferating
tissues such as bone marrow or
those comprising the gastrointestinal
tract. From this model, we will identify parameter ranges,
in terms of dose and period, needed to prevent further growth of the tumor.
One chemotherapeutic
regimen used, as stated by Birkhead
et al. [l], is “the maximallytolerated dose is given as frequently as the rate of bone marrow recovery permits.”
Using the
model developed in this paper, we will investigate
this chemotherapeutic
regimen.
The model
will show for a given dose what the optimal period is to have maximal tumor cell kill. We will
show that in some cases the model confirms Birkhead’s regimen and in others this is not the
“best” way to deliver the chemotherapeutic
drugs.
Another method of increasing the ability of cycle-specific drugs to destroy the tumor (while
not overly destroying
normal tissue) is to provide growth factors to the tumor and/or normal
One such type of growth factor used is exogenous estrogen which is used in treating
tissue.
breast cancer. This increases the tumor cell proliferation
to make the tumor more susceptible to
the chemotherapeutic
drugs. Another class of growth factors used are the hemopoietic
growth
factors (HGF) such as granulocyte
colony-stimulating
factor (G-CSF), granulocyte-macrophage
and interleukin-3
(IL-3). These growth factors are used
colony-stimulating
factor (GM-CSF),
in (AML) to increase the percentage of cells in the S phase (the phase which many chemotherapeutic drugs are most active) and in breast cancer to increase the levels of circulating
leukocytes
(white blood cells). Bhalla et al. [9] state that (G-CSF), (GM-CSF),
and (IL-3) increase about
two to four times the number of (AML) blasts in the S phase while Demetri [lo] states that
these (HGF’s) allow larger doses of chemotherapy
to be safely given because of the increased
circulating
leukocytes.
This model will take into account these growth factors by varying appropriate parameters
such as cell growth rates and show how they increase the effectiveness of the
cycle-specific chemotherapeutic
agents.
2.

MODEL

A two-dimensional
linear differential equation with periodically
pulsed and periodically
piecewise-continuous
chemotherapy
is used to describe the effects of chemotherapy
on a tumor. The
basic model is similar to those described by Eisen and Schiller [5] who describe a two-compartment
model, and Birkhead et al. [l] who include resistant compartments
for both the cycling and
noncycling
cells, thus increasing the dimension
of their model to four. Both examine similar
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models to describe basic tumor growth. However, the model in this paper not only identifies the
chemotherapeutic
effects more explicitly, but more importantly
it models the effects of the drugs
on the normal

tissue.

Some basic assumptions
are made here to keep the model tractable.
First, we only study a linear
system (first-order kinetics) to describe tumor growth. This limits the model to either exponential
growth or decay without any intermediate
equilibrium.
Nevertheless,
this is an acceptable first
approach since a successful chemotherapeutic
regimen will prevent the tumor from growing near
its carrying capacity, so that the nonlinear effects of logistic or Gompertz growth will be minimal,
allowing
exponential
of growth

us to use the simpler
growth
factors).

between

model.

Birkhead

doses. Second,

In their model,

et al. [l,ll]

the parameters

Eisen and Schiller

and Kuzma

will be constant

[5] incorporate

et al. [6] also utilize
(except

nonconstant

for the case
growth,

but

we will avoid this and focus more on the chemotherapeutic
aspects of the model. Third, we do
not take into account spatial or age effects. That is, the resources and chemotherapeutic
drugs
are assumed to reach all cells equally, and cells of all ages are affected uniformly (note though
that this model does take into account natural cell decay). Fourth, Swan [4] (along with many
others) states that the cycling compartment
has four subcompartments
or phases including the
gap period (Gi), the synthetic period (S), the second gap period (Gz), and mitosis (M) (see
Figure 1). To eliminate undue complications,
we will combine the four subcompartments
of the
cycling phase into one to yield a two-compartment
model with both a cycling and a resting
compartment.
Finally, even with cycle-specific drugs there are actually no absolutely safe cells
(both resting and proliferating
cells are affected to some extent) though the faster proliferating
cells will definitely be affected more by the drug. In the present model, we will nonetheless assume
that the resting cells (Go) are not effected by the drugs. It is important
to note that making the
system more complex does not necessarily make it more useful. The simpler system allows us to
view many interesting
features of cycle-specific chemotherapy
without the undue complexity of
the detailed mathematics.
Even with these assumptions,
the model still shows many interesting
dynamics and can address some of the major questions of chemotherapy
such as: will the tumor
grow or decay, how will the major parameters
(dose and period) affect the outcome, and what is
the optimal regimen to deliver the drugs.

1. Cell-cycle.

Figure

2.1.

Two-Compartment

Model

The form of the two-compartment

%

model as described

(i(
$y=

P

ff-P-V
P

in Figure

-P-r

2 is

>( >
Xl

x2

(

(1)

where the parameters
are all constant, positive, and defined as follows: a, cycling cells growth
rate; p, rate which cycling cells become noncycling; 71,natural decay of cycling cells; /3, rate which
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noncycling
cells become cycling; y, natural decay of noncycling
cells (optional).
The elements
of the vector (zi, ~2)~ E 3 represents the cycling and noncycling tumor cell msss, respectively.
We will assume that CY> 7) (positive net growth rate), i.e., in the absence of chemotherapy,
the
tumor will grow without bound. We will also assume that a - p- r~ < 0, i.e., a large number
of cells move to the noncycling
about

20% of the tumor

Thus,

the generalized

or quiescent

compartment.

cells are cycling.

linear system

To simplify

Birkhead

et al. [l] suggest

the form, let a = a - /J-

that

only

r) and 7 E 0.

is

(2)
where a,P,p
that

>_ 0. Birkhead

et al. [l] give one set of parameter

fit the above conditions,

namely,

r

from breast

cancer

data

r

,
CI

L

Cycling Cells
a

values

a = 0.5, p = 0.218, q = 0.477, ,LI= 0.05.

&?8tin4f

Xl

Cell.8

x2
P

\

/

.
Y

rl
Figure 2. Two-compartment

diagram.

Now we examine the periodic chemotherapeutic
conditions.
Since this model describes cyclespecific chemotherapy,
the drugs will only affect the cycling cells, 21. We will examine two types
of chemotherapeutic
effects. The first is similar to that used in [12], i.e., a pulsing condition.
This describes a constant instantaneous
cell kill at each period of dose. The pulsing periodic
condition

is
G,+

=

(fy)

y)&-,

(3)

where 0 < f(D) < 1 is the survival fraction (which is a decreasing function of dose D), and
r is the period between doses. T+ refers to the instant after the drug is given and T- refers to
the instant prior to the dose of the drug. Specific forms of f (II) can be found in [12). Also,
Birkhead et al. (1) examine 0.05 2 f(D) 2 0.4.
For the piecewise

continuous

case, model (2) will be modified

as

The function g(t) is a piecewise continuous
function describing the chemotherapeutic
effects on
the tumor. Webb uses a similar model in his study [2], where he uses a step function to model
the chemotherapeutic
e;fects. We will investigate the model using the exponential
decay function
(Figure 3)
g(t) = he-7(‘-“T),
n?- I t < (n + 1)7,
(5)
where h is the cell kill parameter
and y is the decay of the drug. However as seen in Webb,
g(t) may take on many other forms as considered appropriate.
In this paper, we will compare
the results of this more realistic model of chemotherapy
with the more mathematically
tractable
pulsed-therapy
model.
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I

nz

(n+l) z

Figure 3. Exponential

2.2.

decay function.

Normal Cells

One of the major drawbacks of chemotherapy is that it also affects normal cell tissue. In the
case of cycle-specific chemotherapy, tissue like bone marrow which proliferates rapidly will be
strongly affected by the drug and this will have to be taken into account when developing a
chemotherapeutic regimen, There are a variety of ways to approach this problem. Panetta [12]
examines the interaction between normal and tumor tissue and the effects of cycle-nonspecific
drugs on them. In many cases such as with bone marrow, there is most likely no interaction
with the tumor, but the drugs still affect it. This is the case that we will examine in the present
model. If we assume that the normal tissue has limited growth between pulses of the drug, then
a suitable constraint equation for pulsed therapy is

D=

w - Y>,

72T5 t < (n + l)T,

(6)

where T(D) is the survival fraction for the normal tissue and y(D) > f(D).
This means that,
the drug affects the tumor cells more than the normal cells. Also in the above equation, 6 is the
growth rate of the normal tissue. For the piecewise case, the limited growth equation for normal
tissue is
jr = S(K - y) - &-Y(t-d,
127 5 t < (n + 1)T.
(7)

Note that the above equations are still linear. Logistic growth can also be used to model the
growth of the normal tissue though, in this case, the equation is nonlinear. The form of the
logistic constraint equation for pulsed therapy is

jl = SY

(1- 8)

9

Ynr+

=

mYn,-

7

7275 t < (n + 1)~.

(8)

The logistic equation with pulsing is solved in [12] and the solution to the linear limited growth
equation is similar and is solved in the following section. Finally, the logistic form for the piecewise
case is
e = by (I - 5) - /&vtt-flt)y,
nr 5 f < (n + 1)~.
(9)

3. PULSED

CASE

The first step in analyzing model (2) with pulsing condition (3) and constraint equation (8) is
to develop solutions for (2) and (8) over one period nT 2 t < (n + 1)~. Once this is accomplished,
we can then apply the pulsing condition to arrive at a linear system of difference equations
(sometimes referred to as the first return map or Poincare map, see [13]) that will describe the
growth of the tumor at each pulse.
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3.1. Normal Tissue
First,

consider

difference

the linear case of limited

equation

normal

tissue growth.

Solving equation

(6) yields the

f(D) {K + (ynr - K) e+}.

Y(n+~)T =

(10)

This has only one equilibrium:
y* = K.RD) (1 - emJ7)
s
1 - T((D)em6’
*
Denoting
for limited

0 < w < 1 as the acceptable
growth

fractional

on the chemotherapeutic

=

f(D)

As shown in [12], this has two equilibrium

Thus,

the constraint

K, the constraint

in terms of dose and period

is

02)

’

1 - T((D)e-+

the logistic constraint

Y(n+l)7

capacity

7(D)(1- e-6T)

manner,

kill of the carrying

regimen

w <

Now, in a similar
difference equation

(11)

is also solved.

Solving equation

(8) yields the

~nrK
ynr

+ (K - ynlnr) e-67

(13)

.

points:

on the chemotherapeutic

regimen

in terms of dose and period

is

w < F(D) - e-6r
-

1_e-6~

(15)

.

In both cases, the cycle-specific
chemotherapeutic
drugs have less effect on these tissues,
primarily
since a much higher percentage of normal tissue is in the resting phase. Therefore,
f(D) > f(D) since more normal than cancerous tissue survives each dose.
3.2.

Effects on Tumor

First, examine equation
(2). Hale and Kocak [13, Chapter 81 provide a good account of
the general solutions to linear systems such as this. The form of the solution given by many
elementary
ordinary differential equation texts is Z(t) = cr<rex1(t-n7) + c&eX2(t-n7),
where the
Xi’s are the eigenvalues, and 6’s are the corresponding
eigenvectors to the right-hand
side matrix
of (2). This solution is defined on the interval nr < t < (n + 1)~. By the choices of signs of
the parameters
on the right hand side matrix of equation (2), one eigenvalue must be positive,
(e.g., Xi), with eigenvector 6 in the first quadrant.
Thus, the tumor will grow in the absence of
chemotherapy.
The other eigenvalue will always be negative. It will be more convenient for us to
write the solution in the form
+(t-nf)

c?(t) = P

(

o

0

P-l&~,

eX2(t-nT)

1275 t < (n + 1)7,

(16)

>

where

P=(E;16)
is referred to as the transformation
nth period.

matrix

and h,

is the tumor

(17)
mass at the beginning

of the
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Now, adding pulsing condition (3), the following difference equation describes the tumor mass
just after each pulse of drug:

ql.+l), =

p(“^d’
e,+-y~~
;)ik.

To determine whether the system is growing or decaying, the eigenvalues or characteristic multipliers of the characteristic matrix

of equation (18), need to be investigated. We will define the eigenvalues of matrix (19) as &,
which can be found in terms of f(o) and r. If

then the chemotherapeutic regimen will destroy the tumor; otherwise the tumor will grow. Therefore, we are interested in finding the bifurcation from growth to decay, i.e.,

(20)
in terms of the survival fraction f(o) (or dose) and period 7.
Also, in the above region, there are some regimens that are more effective than others. The
most effective chemotherapeutic regimen is therefore defined as

(21)
for each fixed f(D). This does not take into account the effect of the drugs on the normal tissue.
We must investigate this expression along with inequalities (12) or (15) when developing effective
chemotherapeutic regimens. This is carried out in the next section.
Define 6 E (&,<Q)~.
It can be observed that &I, [lz > 0 and &I, 522 have opposite signs
(this is true because of the signs of a,,@, and p). We can write matrix (19) as
1

(J11t22ex17

det(P)

-

J21J22 (exlT

Call matrix (22) CM.

&2t21ex27)
-

f+)

f(D)
f(o)

-t&2

(exzT

(511J22ex2T

-

-

exzT)

E12521+)

(22)

The eigenvalues of CA4 are

wq,
Calculating the trace(CM)

r) =

trace(CM)

f d(trace(CM))2

- det(CM)

2

and det(CM),

(23)

we get

det(CM)

3 f(D)e(X1+X2)’

3 (gf(o)

- h)eXIT - (hf(D)

> 0

(24)

and
trace(CM)

- g)e’2T > 0,

(25)

where
51162
’

E

det(P)’

and

h+&

It can be seen that both trace(CM) and det(CM) are positive because of the signs of the elements
of the eigenvectors. Therefore, maxi (I%(f(D), T)/) = x,(f(B),~).
By the correct choice of the
dose and period, we are able to force xl (f(o), 7) < 1, thus eliminating the tumor.
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Figure 4. Bifurcation diagram: f(D) = Zf(D).
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Figure 5. Bifurcation diagram: f(D) = 4f(D).

3.3. Results for Pulsed

Therapy

First, we will examine the bifurcation diagram of the model with respect to survival fraction f(D) and period r, that is, investigate the graph of the bifurcation equation (20) with i = 1
and the constraint equation (12) or (15). Using the parameters listed in Section 2.1, w = 0.5,
and 6 = 0.1 along with the logistic constraint equation (15), we obtain Figu_re4 for y(D) = 2f(D)
(normal tissue survives twice as well as tumor tissue) and Figure 5 for f(D) = 4f(D) (normal
tissue survives four times as well as tumor tissue). The tumor condition curve represents the
bifurcation from tumor reduction to tumor growth and the normal condition curve represents
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the bifurcation from overdestruction of normal tissue to acceptable normal cell loss. From these
we can see the area, in parameter space, of acceptable dose and period that will eliminate the
cancer cells while maintaining the normal cells at a level of at least half their carrying capacity.
As can be seen, this region is not small, so, given that we have a prescribed dose to administer,
what is the optimal period to deliver that dose ? To answer this question, we will minimize
xi(f(D),
T) with respect to T. One might assume that for a given survival fraction, the optimal
frequency to administer the drug, (without considering normal tissue) would be continuously. But,
investigating equation (21), it can be seen that the optimal period is actually greater than 7 NN0
(continuously delivering drugs). This is because by allowing some time between each dose, more
resting cells are permitted to move to the cycling compartment, and so there are more cycling cells
to be killed when the next dose is given. Also, it should be noted that giving the drugs at a very
rapid rate will destroy the normal tissue at too great a rate! Thus, a calculation of the optimal
period is extremely practical. For example, with f(D) = 0.25, the optimal period to deliver the
drug is r zz 8 (minxi with respect to T), see Figure 6, while an acceptable period (11 < 1)
ranges over the large interval 0 < 7 < 40. In general, the optimal period is shown in Figure 7
for 0 < f(D) < 0.9. As can be seen, more effective drugs (smaller f(D)) optimal periods are
larger then less effective ones, thus allowing the normal tissue more time to recover.

1.2
I’

1.15

L

1.1

2
.a

1.05

8
2
zi

1

x3

0.95

0.9

0.85

0.8

Figure 6. 1l(f(D),~)

VS. T, f(D)

=

0.25.

Now, consider the chemotherapeutic regimen stated by Birkhead et al. [l]. That is, “the
maximally-tolerated
dose is given as frequently as the rate of bone marrow recovery permits.”
Before seeing if our model agrees with this method, we need to consider what it is meant by this
regimen. There are two possibilities; either administer the drug rapidly but do not use a strong
dose, or allow higher doses but do not administer them as often. By looking at the bifurcation
diagram for T(D) = 2f(D) (F’g
1 ure 4) and the optimal period graph (Figure 7), we observe that
the calculated optimal period is a better regimen if less of a dose (survival fraction f(D) > 0.3) is
given more frequently and Birkhead’s is better if the opposite holds true. This can be observed in
Figure 8 by noting where the optimal period curve and the normal condition curve (6 = 0.1) cross.
If the survival fraction is to the right of this intersection, then the optimal period is best and if
it is to the left then it is not. Of course, the parameters chosen are just one possible acceptable
set; thus, as stated above this is only meant to be a qualitative look at the problem.
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Figure 7. Optimal period vs. f(D).
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Figure 8. Bifurcation with optimal period.
In many cases, the clinician would prefer to give a larger dose then is acceptable by conventional
methods. The problem, as can be seen in Figure 8, is that these large doses (small f(D)) must be
administered over a larger then optimal period to prevent overdestruction of the normal tissue.
In the case of reduced leukocyte production because of damage to the bone marrow, (HGF’s) are
used to help counteract this problem by increasing leukocyte production. This process is modeled
mathematically by increasing the growth rate, S, of the normal tissue equation (either equation (6)
or (8)). As can be seen from Figure 8, a higher growth rate for the normal tissue increases the
region of acceptable drug regimens, thus allowing higher doses of chemotherapeutic drugs to
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Figure 9. T = 20, f(D) = 0.275.
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Figure 10. T = 7.25, f(D) = 0.275.
be given at their optimal period. If 7 = 20 (the best period without growth factors, 6 = 0.1)
and f(D) = 0.275, then there is about a 64.7% reduction in tumor mass. But if growth factors
are given (S = 0.5), then the optimal period of T = 7.25 can be used and there is about a
82.2% reduction in tumor mass, which is a 27% increase in tumor reduction over the nonoptimal
period! Figures 9 and 10 show the phase planes (resting vs. proliferating) for each case. Observing
Figure 9, we can see why the nonoptimal period does not have as large of a cell kill as the optimal
case. The graph shows that the proliferating cancer cells are able to start regrowth before the
next dose is given. Thus, this regimen is not optimal since the dose is too large.
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Figure 11. Beta = 0.05, 15 doses.
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Figure 12. Beta = 0.1, 15 doses.

Another use of (HGF’s) is with (AML). They are used to increase the ratio of proliferating to
resting cells, thus increasing the cell-kill of a cycle-specific drug. This is modeled by an increase
in the parameter /3, which is the rate in which resting cells become proliferating, but can also be
related to an increase in the cell growth rate. One question is: how does an increase in /3 affect
the maximum eigenvalue of the characteristic polynomial? IZxamining the derivative of xr with
respect to p, it can be seen that x,(/3) is a decreasing function of /I > 0. Thus, by increasing
the rate at which resting cells become proliferating, the characteristic multiplier 11 decreases,
which means there is a larger cell-kill. This can be seen in Figure 6. Next, we note that the
optimal period decreases as p is increased (see Figure 7). This can be understood as the cells
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Figure 14. Tumorreduction.
are moving into the cycling compartment faster so we arrive at the optimal period faster. The
most important fact is that by introducing a growth factor the same number of doses can have a
larger overall effect on the (AML). This can be seen in Figures 11 and 12. With the previously
stated parameters, it is calculated that fifteen doses of a drug with (AML) survival fraction
of f(D) = 0.25, period of T = 8 and p = 0.05 will reduce the amount of (AML) by about 85.6%,
while reducing it 97.1% with /3 = 0.1. In this csse, there is a 13.4% increase in tumor reduction.

4. PIECEWISE

CASE

The model that we use in this case is based on equations (4),(5) and the normal tissue condition (9). Analytic solutions to the tumor equation can be found in terms of confluent hypergeo-
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Figure 15. Bifurcation curves with optimal period curve.

metric functions (in preparation), but for the purposes of this article we only investigate numerical
solutions to the above equations. In particular, we are interested in comparing the results of the
pulsed therapy with those of the piecewise therapy. Note that the parameter y in the piecewise
case describes the decay rate of the chemotherapeutic drug. A large value of y therefore, corresponds to the effects of the drug decaying away quickly. This is qualitatively equivalent to a high
survival fraction, f(D), in the pulsed case. First, the parameters are set as in the pulsed case
with the new parameter h = 0.5 for both the normal and tumor equations. The first comparison
of the two cases is with their bifurcation diagrams. Note the similarities between Figures 13
and 5. Both show similar regions in parameter space for acceptable period and strength, The
main difference between the two is that in the piecewise case, since the drugs destroy cells over
the complete period (not instantly as in the pulsed case), there is not the instantaneous drop in
normal cell mass as there is in the pulsed case. Thus, in the piecewise case, we are not concerned
about the cell mass instantly dropping below its critical value. Therefore, this model shows for
larger drug doses. Note next the similarities between Figures 14 and 6. It should be recalled that
the minimum eigenvaiue means highest tumor reduction in Figure 6. Finally, Figure 15 shows
the optimal period curve along with the bifurcation curves of both normal and cancerous tissue.
The most interesting point to be made here is that unlike the pulsed case, the optimal period
curve is completely in the acceptable region. Therefore, if we are to compare the optimal period
in the piecewise case to the regimen stated by Birkhead et al. (“the maximally-tolerated dose
is given as frequently as the rate of bone marrow recovery permits”), we can see that they are
basically equivalent. That is, if the clinician is to give a strong dose (r small), then the optimal
period and the smallest period that allows bone marrow recovery are almost identical.
5. DISCUSSION
For chemotherapeutic drugs to be useful, they must be given to the patient at an appropriate
interval with an effective dose. The clinician must also take into account the effects of the drugs
on the normal tissue. Otherwise, a given drug regimen might eliminate the tumor but also destroy
the normal tissue, or even have no detrimental effect at all upon the tumor. Thus far, few of the
mathematically constructed models have considered these situations, and most drug protocols
are developed empirically. It is our hope that this model gives some indication of how to better
administer the drugs in order to more effectively destroy the cancerous cells.
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The most basic question that can be asked about a chemotherapeutic regimen is, how much is
enough and how much is too much? We have shown using the characteristic multipliers of the
Poincare maps that there is a bifurcation or boundary (in terms of survival fraction and period),
between regimens that will and will not eliminate the tumor mass. As noted earlier, this is only
intended to be a qualitative approach, and quantitative details will of course very from patient to
patient. Clearly, a bifurcation diagram is not enough to develop a good chemotherapeutic regimen
since it includes modalities like continuously giving a very large dose of the drug. Obviously this
will eliminate the tumor mass, but it will also kill the patient! Thus, the use of the constraint
equation that models the effects of the drugs on the normal tissues must be included.
However, with the constraint equation added, there is still a wide range of acceptable drug
regimens. Thus, we look for the optimal regimen. In doing this, we have shown that the best
drug protocol is not delivering the drug as often as possible and as strongly as possible, but
rather at the optimal period and dose. Because of the constraint of normal tissue survival, this is
not always possible with each dose (survival fraction). That is, for stronger doses, the period of
delivery must be broadened at nonoptimal periods to prevent overly destroying the normal tissue
or a weaker dose must be administered.
Growth factors increasingly are being used to help cycle-specific chemotherapeutic drugs work
more effectively. This is one area where much medical research has been done, so in principle
the medical results and the mathematical models can be closely compared to improve our understanding of how the various growth factors are affecting the use of chemotherapeutic drugs on
cancerous tissue. The pulsed model clearly shows that incorporating growth factors in (AML)
increases the cell kill by about 13%-14010,and reduces the number of doses needed to accomplish
the same results, while in breast cancer they allow larger doses of chemotherapy to be administered at optimal periods to obtain maximal cell kill. In this case, the growth factors increased
the cell kill to about 27%-a significant improvement.
The piecewise model of chemotherapy is the more realistic of the two studied in this paper,
but mathematically it is much more difficult to investigate. As noted above, it can be solved
analytically, but this is mathematically very intensive especially when compared to the pulsed
therapy case. By comparing the various bifurcation diagrams and optimal period diagrams, we
can observe that the results obtained numerically using the piecewise model are qualitatively very
similar to those obtained with the pulsed case. Only a few differences are noted. Because of this,
very similar qualitative
results may be drawn from either model. Therefore, it would be wise
to choose the mathematically more appropriate model-the
pulsed therapy model. However, if
circumstances permit and a more realistic approach to the chemotherapeutic effects is desired,
the piecewise model is the better choice.
One of the limitations of this model is it does not take into account varying parameters. For
example, it is known that over time the chemotherapeutic doses have more effect on the the normal
tissue and less effect on the tumor mass (resistance, etc.) or the drugs reduce the carrying capacity
of the normal tissue over time. Future work will include modifying some of these assumptions,
thereby formulating a more comprehensive model. Even accepting the simplifications, this model
illustrates some of the more important dynamics of chemotherapy. It identifies, for example,
parameter regions of acceptable chemotherapeutic regimens, some of which reinforce regimens
already developed empirically, and also it indicates the effects of the drugs on normal tissue and
how this affects the chemotherapeutic process. The model also identifies how the use of growth
factors increases the effectiveness of the drugs, again reinforcing much of the clinical work done
in the area of cancer chemotherapy.
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